HDAC5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL28250	0.57	14/20
SCHEMBL29476	0.57	14/20
SCHEMBL31064	0.57	14/20
SCHEMBL30259	0.57	14/20
SCHEMBL28328	0.61	13/20
SCHEMBL28329	0.61	13/20
SCHEMBL28330	0.61	13/20
SCHEMBL29695	0.61	13/20
SCHEMBL30199	0.61	13/20
Vorinostat (SCHEMBL9018)	1.00	12/20
Iodipamide (SCHEMBL37678)	0.41	12/20
Trichostatin (SCHEMBL19886)	1.00	10/20
SCHEMBL34229	0.51	10/20
SCHEMBL19539	0.48	10/20
SCHEMBL28840	0.61	9/20
SCHEMBL28841	0.61	9/20
SCHEMBL28842	0.61	9/20
SCHEMBL29955	0.61	9/20
SCHEMBL29956	0.61	9/20
SCHEMBL21138	0.49	9/20

Clinical trials — most relevant to HDAC5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma	PHASE2	COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Voronistat in Pediatric Patients With Drug Resistant Epilepsy	PHASE2	UNKNOWN
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer	PHASE2	UNKNOWN
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma	PHASE2	RECRUITING
Chidamide Combined With Toripalimab in Sarcoma	PHASE2	COMPLETED
An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma	PHASE2	COMPLETED
Vorinostat in Children	PHASE1/PHASE2	COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors	PHASE1	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors	PHASE1	COMPLETED
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours	PHASE1	COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia	PHASE1	COMPLETED
SHP-141C in Plaque Type Psoriasis	PHASE1	COMPLETED
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL	PHASE1	ACTIVE_NOT_RECRUITING
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction	PHASE1	COMPLETED
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid	EARLY_PHASE1	COMPLETED
ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer	EARLY_PHASE1	WITHDRAWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
Chi-GVM Regimen for the Treatment of R/R PTCL	nan	UNKNOWN
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer	nan	WITHDRAWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Imaging Histone Deacetylase in the Heart	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a HDAC5 binder may also engage these)

Protein	Name	Similarity
Q80ZH1	—	1.000	Q80ZH1 →
Q9Z2V6	—	1.000	Q9Z2V6 →
Q5R902	—	1.000	Q5R902 →
P83038	—	1.000	P83038 →
Q99P99	—	1.000	Q99P99 →
HDAC4	Histone deacetylase 4	1.000	landscape →
HDAC9	Histone deacetylase 9	1.000	landscape →
Q58NQ4	—	1.000	Q58NQ4 →
Q6NSM8	—	1.000	Q6NSM8 →
Q9H334	—	0.999	Q9H334 →
P23899	—	0.999	P23899 →
NFRKB	Nuclear factor related to kappa-B-binding protein	0.998	landscape →
Q03365	—	0.998	Q03365 →
Q6NZM9	—	0.998	Q6NZM9 →
Q6P4S6	—	0.997	Q6P4S6 →
P27889	—	0.997	P27889 →
P35680	—	0.997	P35680 →
Q2EJA0	—	0.997	Q2EJA0 →
Q4VYS1	—	0.997	Q4VYS1 →
SIK3	Serine/threonine-protein kinase SIK3	0.997	landscape →
Q62901	—	0.997	Q62901 →
P62515	—	0.996	P62515 →
P24610	—	0.996	P24610 →
Q498D1	—	0.996	Q498D1 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.996	landscape →
MAP3K9	Mitogen-activated protein kinase kinase kinase 9	0.996	landscape →
P40645	—	0.996	P40645 →
P40647	—	0.996	P40647 →
A0A8C0NGY6	—	0.996	A0A8C0NGY6 →
P20823	—	0.996	P20823 →